AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: (Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: (Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: (Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: (Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: (Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: (Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: (Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: (Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: (Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: (Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted.
Study NCT02867800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Marrow infusion
Description: (Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: (Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used.
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: (Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used.
Study NCT01937585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner and CDC brochure condition
Description: Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
Study NCT01937585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC brochure only condition
Description: Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
Study NCT00839787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
Study NCT00839787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
Study NCT02148315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: garden
Study NCT00808470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-carotene, vitamins C and E, magnesium
Description: 6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene.
Study NCT01777126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Protocol (ONP) group
Description: For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
Study NCT01777126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
Study NCT00808470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
Study NCT00619125 — intervention group
Intervention type: OTHER
Intervention: palm pilot recording responses to questionnaires
Description: Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
Study NCT03690362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 and VNRX-5022
Description: intravenous infusion
Study NCT02324621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral ONC201
Description: Given PO
Study NCT02324621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02324621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00893971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001
Description: Inhaled PT001, single dose
Study NCT00893971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005
Description: Inhaled PT005, single dose
Study NCT00893971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: Inhaled PT003, single dose
Study NCT00893971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 + PT005
Description: Inhaled PT001 + PT005, single dose
Study NCT03151213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Pregabalin 150mg before RFA of liver cancer
Study NCT03151213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo before RFA of liver cancer
Study NCT04691687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: IV loop diuretic therapy
Study NCT04691687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Solution
Description: IV Placebo comparator
Study NCT00978341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150mg capsules BID for 7.5 days
Study NCT00978341 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo for pregabalin
Description: Placebo capsules BID for 7.5 days
Study NCT04888858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)
Description: As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
Study NCT04455737 — intervention group
Intervention type: OTHER
Intervention: injection of indigo carmine
Description: Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
Study NCT04063722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified Benelli procedure
Description: use of modified Benelli procedure for surgical treatment of gynecomastia
Study NCT04063722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Benelli procedure
Description: use of modified Benelli procedure for surgical treatment of gynecomastia
Study NCT02259829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Description: Fixed dose combination tablet
Study NCT02259829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02259829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study NCT03099226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo blue hard gelatine capsules
Study NCT03099226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
Study NCT04848246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: This group received Bupropion 150 mg twice daily for 10 weeks
Study NCT04848246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Change Communication
Description: This group will receive Behavioural Change Communication
Study NCT05804253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus augmentation
Description: Maxillary sinus grafting with 2 different xenogenic materials
Study NCT03630029 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FeS and SnPP
Description: Escalating doses of drug will be compared for biomarker changes
Study NCT03017547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC14
Description: Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
Study NCT03017547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline for infusion
Study NCT02131727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Hygiene Improvement Intervention
Description: Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
Study NCT02131727 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ask Me 3
Description: Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers.
Study NCT03265015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.
Study NCT03265015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.
Study NCT03265015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas.
Study NCT03265015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas.
Study NCT03712449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM®
Description: Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).
Study NCT03712449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX Cosmetic®
Description: BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
Study NCT03712449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BELKYRA®
Description: BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).
Study NCT03712449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica
Description: SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
Study NCT04083924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound
Description: Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
Study NCT01620333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
Study NCT05256212 — intervention group
Intervention type: OTHER
Intervention: exposure to environmental contaminants
Description: to measure levels of contaminants in different matrixes
Study NCT02706951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Capsule; Oral
Study NCT02706951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study NCT02706951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Upadacitinib
Description: Tablet; Oral
Study NCT02706951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Capsule; Oral
Study NCT02516865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
Study NCT02516865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle weights
Description: Worn during typical daily activities.
Study NCT03801681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG holter monitoring
Description: patients will be monitored using ECG-holter
Study NCT03287778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine
Description: Max dose of 400 mg QD PO
Study NCT03287778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos will be administered.
Study NCT01476813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: comparison of different dosages of drug
Study NCT01476813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: comparison of different dosages of drug versus comparator
Study NCT05512078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone positioning surgical guide
Description: patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
Study NCT05512078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone positioning surgical guide
Description: patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
Study NCT03016598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
Study NCT03016598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
Study NCT00704171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Tissue Closure Techniques
Description: Standard Tissue Closure Techniques (sutures and staples only)
Study NCT00704171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleuraSeal Lung Sealant System
Study NCT00704171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PleuraSeal Lung Sealant System
Study NCT01620333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
Study NCT04239196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab and IV steroids combination
Description: Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).